CRISPR screens identify gene targets at breast cancer risk loci.
Breast cancer risk
Functional phenotypic screens
Post GWAS
Target discovery
Journal
Genome biology
ISSN: 1474-760X
Titre abrégé: Genome Biol
Pays: England
ID NLM: 100960660
Informations de publication
Date de publication:
29 03 2023
29 03 2023
Historique:
received:
18
09
2022
accepted:
16
03
2023
medline:
31
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Genome-wide association studies (GWAS) have identified > 200 loci associated with breast cancer risk. The majority of candidate causal variants are in non-coding regions and likely modulate cancer risk by regulating gene expression. However, pinpointing the exact target of the association, and identifying the phenotype it mediates, is a major challenge in the interpretation and translation of GWAS. Here, we show that pooled CRISPR screens are highly effective at identifying GWAS target genes and defining the cancer phenotypes they mediate. Following CRISPR mediated gene activation or suppression, we measure proliferation in 2D, 3D, and in immune-deficient mice, as well as the effect on DNA repair. We perform 60 CRISPR screens and identify 20 genes predicted with high confidence to be GWAS targets that promote cancer by driving proliferation or modulating the DNA damage response in breast cells. We validate the regulation of a subset of these genes by breast cancer risk variants. We demonstrate that phenotypic CRISPR screens can accurately pinpoint the gene target of a risk locus. In addition to defining gene targets of risk loci associated with increased breast cancer risk, we provide a platform for identifying gene targets and phenotypes mediated by risk variants.
Sections du résumé
BACKGROUND
Genome-wide association studies (GWAS) have identified > 200 loci associated with breast cancer risk. The majority of candidate causal variants are in non-coding regions and likely modulate cancer risk by regulating gene expression. However, pinpointing the exact target of the association, and identifying the phenotype it mediates, is a major challenge in the interpretation and translation of GWAS.
RESULTS
Here, we show that pooled CRISPR screens are highly effective at identifying GWAS target genes and defining the cancer phenotypes they mediate. Following CRISPR mediated gene activation or suppression, we measure proliferation in 2D, 3D, and in immune-deficient mice, as well as the effect on DNA repair. We perform 60 CRISPR screens and identify 20 genes predicted with high confidence to be GWAS targets that promote cancer by driving proliferation or modulating the DNA damage response in breast cells. We validate the regulation of a subset of these genes by breast cancer risk variants.
CONCLUSIONS
We demonstrate that phenotypic CRISPR screens can accurately pinpoint the gene target of a risk locus. In addition to defining gene targets of risk loci associated with increased breast cancer risk, we provide a platform for identifying gene targets and phenotypes mediated by risk variants.
Identifiants
pubmed: 36991492
doi: 10.1186/s13059-023-02898-w
pii: 10.1186/s13059-023-02898-w
pmc: PMC10053147
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
59Informations de copyright
© 2023. The Author(s).
Références
Genes Dev. 2001 Jan 1;15(1):50-65
pubmed: 11156605
Science. 2021 Apr 9;372(6538):156-165
pubmed: 33833118
Cancer Res. 2016 May 1;76(9):2612-25
pubmed: 26941286
Hum Mol Genet. 2015 May 15;24(10):2966-84
pubmed: 25652398
Nat Commun. 2019 Apr 15;10(1):1741
pubmed: 30988301
Cell. 2018 Aug 9;174(4):1034-1035
pubmed: 30096302
Nat Genet. 2020 Jun;52(6):572-581
pubmed: 32424353
Oncogene. 2002 Jan 3;21(1):128-39
pubmed: 11791183
Cancer Discov. 2018 Nov;8(11):1422-1437
pubmed: 30181244
PLoS Genet. 2019 Dec 12;15(12):e1008489
pubmed: 31830040
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Genome Biol. 2020 Jan 7;21(1):7
pubmed: 31910864
Nat Commun. 2017 May 23;8:15403
pubmed: 28534478
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14146-51
pubmed: 20660721
Science. 2016 Nov 11;354(6313):769-773
pubmed: 27708057
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Genet. 2017 Nov;49(11):1602-1612
pubmed: 28945252
Br J Cancer. 2020 Feb;122(4):506-516
pubmed: 31839677
Nat Genet. 2020 Jan;52(1):56-73
pubmed: 31911677
Nat Biotechnol. 2016 Feb;34(2):184-191
pubmed: 26780180
Elife. 2022 Dec 14;11:
pubmed: 36515579
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Breast Cancer Res Treat. 2016 Aug;158(3):441-54
pubmed: 27393618
Mol Cell. 2021 May 20;81(10):2183-2200.e13
pubmed: 34019788
Nature. 2020 Apr;580(7801):136-141
pubmed: 32238925
Am J Hum Genet. 2013 Dec 5;93(6):1046-60
pubmed: 24290378
Nat Genet. 2013 Apr;45(4):371-84, 384e1-2
pubmed: 23535731
Nat Commun. 2014 Sep 23;4:4999
pubmed: 25248036
Nat Genet. 2018 Jul;50(7):968-978
pubmed: 29915430
Nat Genet. 2016 Apr;48(4):374-86
pubmed: 26928228
Cell Commun Signal. 2021 Jul 28;19(1):80
pubmed: 34321041
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Commun. 2016 Sep 07;7:12675
pubmed: 27601076
Cancer Manag Res. 2020 May 25;12:3891-3902
pubmed: 32547225
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Genome Biol. 2021 Dec 20;22(1):344
pubmed: 34930414
Eur J Pharmacol. 2020 Aug 5;880:173100
pubmed: 32320704
Am J Hum Genet. 2021 Dec 2;108(12):2284-2300
pubmed: 34822763
Proc Natl Acad Sci U S A. 2018 May 22;115(21):E4806-E4814
pubmed: 29735662
Genome Biol. 2014;15(12):554
pubmed: 25476604
Nat Methods. 2018 Apr;15(4):271-274
pubmed: 29457792
Oncogene. 2006 Mar 2;25(9):1299-310
pubmed: 16247450
Nat Commun. 2018 Dec 21;9(1):5416
pubmed: 30575746
Cell. 2016 Nov 17;167(5):1369-1384.e19
pubmed: 27863249
Curr Protoc Mol Biol. 2015 Jan 05;109:21.29.1-21.29.9
pubmed: 25559105
Cancer Res. 2021 Feb 1;81(3):525-534
pubmed: 33115801
Genet Epidemiol. 2018 Jul;42(5):418-433
pubmed: 29808603
Cell. 2019 Mar 7;176(6):1516
pubmed: 30849375
Genome Biol. 2020 Jan 7;21(1):8
pubmed: 31910858
Am J Hum Genet. 2021 Jul 1;108(7):1190-1203
pubmed: 34146516
Am J Hum Genet. 2020 Oct 1;107(4):778-787
pubmed: 32871102
Cancers (Basel). 2020 Jan 10;12(1):
pubmed: 31936698
Biochem Cell Biol. 2021 Oct;99(5):554-561
pubmed: 33621155
Nature. 2021 Feb;590(7845):300-307
pubmed: 33536621
Genome Biol. 2021 Jan 26;22(1):47
pubmed: 33499898
Nat Genet. 2015 Aug;47(8):856-60
pubmed: 26121088
Am J Transl Res. 2020 Feb 15;12(2):310-331
pubmed: 32194886
J Cell Biochem. 2020 Mar;121(3):2197-2208
pubmed: 31724223
Am J Hum Genet. 2018 May 3;102(5):890-903
pubmed: 29727689
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
EMBO J. 2020 Jan 2;39(1):e102406
pubmed: 31782549
Am J Hum Genet. 2013 Apr 4;92(4):489-503
pubmed: 23540573
Am J Hum Genet. 2015 Jan 8;96(1):5-20
pubmed: 25529635
Cell. 2020 Jul 23;182(2):481-496.e21
pubmed: 32649862
Nat Commun. 2017 Jan 16;8:14049
pubmed: 28091601
Cell Syst. 2016 Sep 28;3(3):302-316.e4
pubmed: 27684187
Nature. 2021 May;593(7858):238-243
pubmed: 33828297
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138
Oncogene. 2020 Aug;39(32):5455-5467
pubmed: 32587399
Am J Hum Genet. 2017 Aug 3;101(2):255-266
pubmed: 28777932
Am J Hum Genet. 2015 Jul 2;97(1):22-34
pubmed: 26073781
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490